Health Care [ 4/12 ] | Biotechnology [ 11/75 ]
NASDAQ | Common Stock
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States.
The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology.
SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 13, 26 | -0.05 Increased by +37.50% | -0.07 Increased by +28.57% |
| Nov 12, 25 | -0.06 Increased by +40.00% | -0.08 Increased by +25.00% |
| Aug 12, 25 | -0.07 Increased by +46.15% | -0.08 Increased by +12.50% |
| May 12, 25 | -0.07 Increased by +66.67% | -0.21 Increased by +66.67% |
| Mar 26, 25 | -0.08 Increased by +68.00% | -0.11 Increased by +25.02% |
| Nov 7, 24 | -0.10 Increased by +69.70% | -0.13 Increased by +21.07% |
| Aug 13, 24 | -0.13 Increased by +58.06% | -0.16 Increased by +18.75% |
| May 14, 24 | -0.21 Increased by +55.32% | -0.16 Decreased by -31.25% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 0.00 Decreased by N/A% | -7.66 M Decreased by -13.67% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 25 | 0.00 Decreased by N/A% | -6.79 M Increased by +4.46% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -6.60 M Increased by +11.63% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -5.81 M Increased by +39.23% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by N/A% | -6.74 M Increased by +17.20% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -7.11 M Increased by +23.30% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -7.47 M Increased by +15.50% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -9.57 M Increased by +13.80% | Decreased by N/A% Decreased by N/A% |